The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InVera Therapeutics (Nasdaq: VERA) announced that the U.S. Food and Drug Administration (FDA) has granted priority review to its Biologics License Application (BLA) for atacicept. The drug is designed to treat IgA nephropathy (IgAN), following positive clinical data from the Phase 3 ORIGIN 3 study. The FDA has set a PDUFA action date for July 7, 2026, with a potential commercial launch anticipated in mid-2026. Alongside this regulatory milestone, the company reported its full-year 2025 financial results, highlighting a robust capital position. Vera Therapeutics confirmed that its current balance sheet is sufficient to fund operations well beyond the drug's approval and initial U.S. market entry. This financial stability, supported by recent equity and debt financing, ensures the company can meet its strategic commercialization goals.